Biochemical studies of immune complexes. II. Purification of immune complexes from sera of patients with malignant melanoma.

S. Quay,G. Murphy,M. Mihm

DOI: https://doi.org/10.1016/0090-1229(83)90116-2

1983-03-01

Clinical Immunology and Immunopathology

Abstract:

What problem does this paper attempt to address?

Association of Pulmonary Artery Pressure Change with Post-Lung Transplantation Survival: Retrospective Analysis of China Registry

Guohui Jiao,Jian Huang,Bo Wu,Chunxiao Hu,Chenyang Gao,Wenhui Chen,Man Huang,Jingyu Chen

DOI: https://doi.org/10.1016/j.jacasi.2022.09.017

2022-01-01

JACC Asia

Abstract:BackgroundExtracorporeal membrane oxygenation (ECMO) has been used as intraoperative hemodynamic support in patients with end-stage lung diseases and pulmonary hypertension undergoing lung transplantation (LT).ObjectivesThe aim of this study was to identify the association of pulmonary artery pressure change during ECMO and post-LT survival.MethodsThe study investigators collected and analyzed the data from Chinese Lung Transplantation Registry. Patients who have severe pulmonary hypertension with intraoperative ECMO support were enrolled. Post-LT mortality and morbidity were further collected and compared.ResultsA total of 208 recipients were included in the study, during which 53 deaths occurred post-LT. All the patients had severe pulmonary hypertension and were supported by intraoperative ECMO. Using eXtreme Gradient Boosting, or XGboost, model method, 20 variables were selected and ranked. Changes of mean pulmonary artery pressure at the time of ECMO support and ECMO wean-off (ΔmPAP) were related to post-LT survival, after adjusting for potential confounders (recipient age, New York Heart Association functional class status before LT, body mass index, pre-LT hypertension, pre-LT steroids, and pre-LT ECMO bridging). A nonlinear relationship was detected between ΔmPAP and post-LT survival, which had an inflection point of 35 mm Hg. Recipients with ΔmPAP ≦35 mm Hg had higher mortality rate calculated through the Kaplan-Meier estimator (P = 0.041). Interaction analysis showed that recipients admitted in LT center with high case volume (≥50 cases/year) and ΔmPAP >35 mm Hg had better long-term survival. The trend was reversed in recipients who were admitted in LT center with low case volume (<50 cases/year).ConclusionsThe relationship between ΔmPAP and post-LT survival was nonlinear. Optimal perioperative ECMO management strategy with experienced team is further warranted.
Critically Ill Patients with COVID-19 with ECMO and Artificial Liver Plasma Exchange

Jian Liu,Yong-Quan Dong,Jie Yin,Guojun He,Xiaoxin Wu,Jianping Li,Yunqing Qiu,Xuelin He

DOI: https://doi.org/10.1097/md.0000000000021012

IF: 1.6

2020-01-01

Medicine

Abstract:COVID-19 is an emerging infectious disease capable of causing severe pneumonia. We aimed to characterize a group of critically ill patients in a single-center study.This was a retrospective case series of 23 patients with confirmed COVID-19-related critical illness in the intensive care unit (ICU) of a hospital in Hangzhou Zhejiang Province between January 22 and March 20, 2020.Of the 23 critically ill patients, the median age was 66 years (interquartile range [IQR] 59-80 years). The median time from disease onset to ICU admission was 10 days (IQR 6-11 days), to mechanical ventilation (MV) was 11 days (IQR 7.75-13 days), to artificial liver plasma exchange was 12 days (IQR 9.75-14.75 days), and to extracorporeal membrane oxygenation (ECMO) was 22 days (IQR 17.5-30 days). Nine patients required high flow oxygen. Fourteen patients received MV. Six required ECMO. Nine received artificial liver plasma exchange. Mortality was 0 at day 28.Mortality was 0 at day 28 in our single-center study. Extracorporeal membrane oxygenation reduced the requirements for ventilator support. Artificial liver plasma exchange significantly reduced inflammatory cytokine levels. These supportive therapies helped to extend the patients' survival times and increase the chance of follow-up treatments.
Association of perioperative transfusion of fresh frozen plasma and outcomes after cardiac surgery

Jake V. Hinton,Zhongyue Xing,Calvin Fletcher,Luke A. Perry,Alexandra Karamesinis,Jenny Shi,Jahan C. Penny‐Dimri,Dhruvesh Ramson,Tim G. Coulson,Reny Segal,Julian A. Smith,Jenni Williams‐Spence,Laurence Weinberg,Rinaldo Bellomo

DOI: https://doi.org/10.1111/aas.14406

2024-03-13

Acta Anaesthesiologica Scandinavica

Abstract:Background Fresh frozen plasma (FFP) transfusion is used to manage coagulopathy and bleeding in cardiac surgery patients despite uncertainty about its safety and effectiveness. Methods We performed a propensity score matched analysis of the Australian and New Zealand Society of Cardiac and Thoracic Surgeons National Cardiac Surgery Database including patients from 39 centres from 2005 to 2018. We investigated the association of perioperative FFP transfusion with mortality and other clinical outcomes. Results Of 119,138 eligible patients, we successfully matched 13,131 FFP recipients with 13,131 controls. FFP transfusion was associated with 30‐day mortality (odds ratio (OR), 1.41; 99% CI, 1.17–1.71; p

anesthesiology
Association Between Perioperative Plasma Transfusion and In-Hospital Mortality in Patients Undergoing Surgeries Without Massive Transfusion: A Nationwide Retrospective Cohort Study.

Xiaohan Xu,Yuelun Zhang,Bo Tang,Xuerong Yu,Yuguang Huang

DOI: https://doi.org/10.3389/fmed.2023.1130359

IF: 3.9

2023-01-01

Frontiers in Medicine

Abstract:BackgroundAn aggressive plasma transfusion is associated with a decreased mortality in traumatic patients requiring massive transfusion (MT). However, it is controversial whether non-traumatic or non-massively transfused patients can benefit from high doses of plasma. MethodsWe performed a nationwide retrospective cohort study using data from Hospital Quality Monitoring System, which collected anonymized inpatient medical records from 31 provinces in mainland China. We included the patients who had at least one record of surgical procedure and received red blood cell transfusion on the day of surgery from 2016 to 2018. We excluded those receiving MT or diagnosed with coagulopathy at admission. The exposure variable was the total volume of fresh frozen plasma (FFP) transfused, and the primary outcome was in-hospital mortality. The relationship between them was assessed using multivariable logistic regression model adjusting 15 potential confounders. ResultsA total of 69319 patients were included, and 808 died among them. A 100-ml increase in FFP transfusion volume was associated with a higher in-hospital mortality (odds ratio 1.05, 95% confidence interval 1.04-1.06, p < 0.001) after controlling for the confounders. FFP transfusion volume was also associated with superficial surgical site infection, nosocomial infection, prolonged length of hospital stay, ventilation time, and acute respiratory distress syndrome. The significant association between FFP transfusion volume and in-hospital mortality was extended to the subgroups of cardiac surgery, vascular surgery, and thoracic or abdominal surgery. ConclusionsA higher volume of perioperative FFP transfusion was associated with an increased in-hospital mortality and inferior postoperative outcomes in surgical patients without MT.
Hemostasis During Extracorporeal Membrane Oxygenation: More Questions

Lin Chen,Zhongheng Zhang,Kun Chen

DOI: https://doi.org/10.1016/j.healun.2020.08.011

2020-01-01

Abstract:We read the study by Durila et al 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar with interest; however, we seek several clarifications. First, a separate study by Yu et al 2 Yu ES, Jeon MJ, Kang KW, et al. The role of platelet function analyzer-200 in predicting perioperative bleeding risk [e-pub ahead of print]. Korean J Intern Med. doi:10.3904/kjim.2019.112, accessed September 9, 2020. Google Scholar showed that the results of platelet function analyzer 200 (PFA 200) are influenced by various factors, such as the use of aspirin and other non-steroidal anti-inflammatory agents, blood group type, hematocrit and time of blood collection, transfusions, and underlying diseases. The severity of surgery might cause bleeding, which affects collagen–epinephrine and collagen–adenosine diphosphate. The conclusion that the pathology of primary hemostasis detected by the PFA 200 (collagen–epinephrine and collagen–adenosine diphosphate) was specific for the extracorporeal membrane oxygenation (ECMO) phase of surgery is not robust and is subject to confounding bias. 3 Zhang Z Model building strategy for logistic regression: purposeful selection. Ann Transl Med. 2016; 4: 111 Crossref PubMed Scopus (192) Google Scholar Second, a continuous intravenous infusion of low-molecular-weight heparin was used to prevent venous thromboprophylaxis, but without dose described. Piwowarczyk et al 4 Piwowarczyk P, Borys M, Kutnik P, et al. Unfractionated heparin versus subcutaneous nadroparin in adults supported with venovenous extracorporeal membrane oxygenation: a retrospective, multicenter study [e-pub ahead of print]. ASAIO J. doi:10.1097/MAT.0000000000001166, accessed September 9, 2020. Google Scholar compared nadroparin with unfractionated heparin during veno-venous ECMO and found no significant difference in the number of thrombotic and hemorrhagic events. In the paper by Durila et al, 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar even with the use of continuous intravenous infusion of low-molecular-weight heparin, 2 patients suffered thrombotic events. Third, the duration of the ECMO in their work is short (5 ± 3 days). The effect of duration of support on outcomes was not provided because we would suggest that the risk of thrombotic events is lower with a shorter duration of ECMO support. Given these considerations, it is difficult for us to completely agree with the conclusion that the PFA 200 analyzer may be used to prevent circuit thrombosis instead of using unfractionated heparin in patients on prolonged ECMO. We believe that a point-of-care test such as the PFA 200 may assist in adjusting anti-coagulant strategy to potentially reduce the use of unfractionated heparin rather than to prevent circuit thrombosis and obviate the use of unfractionated heparin altogether, especially in patients on prolonged ECMO support.
Haematological Trends and Transfusion during Adult Extracorporeal Membrane Oxygenation: A Single Centre Study

Elliott T Worku,April M Win,Dinesh Parmar,Chris Anstey,Kiran Shekar

DOI: https://doi.org/10.3390/jcm12072629

2023-03-31

Abstract:The temporal trends in haematological parameters and their associations with blood product transfusion requirements in patients supported with extracorporeal membrane oxygenation (ECMO) are poorly understood. We performed a retrospective data analysis to better understand the behaviour of haematological and coagulation parameters and their associations with transfusion requirements during ECMO. Methods: Patient demographics, haematological and coagulation parameters, plasma haemoglobin and fibrinogen concentrations, platelet count, the international normalised ratio (INR), the activated partial thromboplastin time (APTT), and blood product transfusion data from 138 patients who received ECMO in a single high-volume centre were analysed. Results: Ninety-two patients received venoarterial (VA) ECMO and 46 patients received venovenous (VV) ECMO. The median (IQR) duration of VA, and VV ECMO was 8 (5-13) days and 13 (8-23) days, respectively. There were significant reductions in haemoglobin, the platelet count, and the fibrinogen concentration upon initiation of ECMO. On average, over time, patients on VV ECMO had platelet counts 44 × 109/L higher than those on VA ECMO (p ≤ 0.001). Fibrinogen and APTT did not vary significantly based on the mode of ECMO (p = 0.55 and p = 0.072, respectively). A platelet count < 50 × 109/L or a fibrinogen level < 1.8 g/L was associated with 50% chance of PRBC transfusion, regardless of the ECMO type, and packed red blood cell (PRBC) transfusion was more common with VA ECMO. APTT was predictive of the transfusion requirement, and the decrement in APTT was discriminatory between VVECMO survivors and nonsurvivors. Conclusion: ECMO support is associated with reductions in haemoglobin, platelet count, and fibrinogen. Patients supported with VA ECMO are more likely to receive a PRBC transfusion compared to those on VV ECMO. Thrombocytopaenia, hypofibrinogenaemia, and anticoagulation effect the likelihood of requiring PRBC transfusion. Further research is needed to define optimal blood management during ECMO, including appropriate transfusion triggers and the anticoagulation intensity.
Risk factors for mortality in patients receiving extracorporeal membrane oxygenation

Junjie Wang,Suiqing Huang,Kangni Feng,Huawei Wu,Liqun Shang,Zhuoming Zhou,Quan Liu,Jiantao Chen,Mengya Liang,Guangxian Chen,Jian Hou,Zhongkai Wu

DOI: https://doi.org/10.1080/0886022X.2024.2395450

Abstract:Objective: Patients on extracorporeal membrane oxygenation (ECMO) are often complex and have a high mortality rate. Currently, risk assessment and treatment decisions for patients receiving ECMO are controversial. Therefore, we sought to identify risk factors for mortality in patients receiving ECMO and provide a reference for patient management. Methods: We retrospectively analyzed the clinical data of 199 patients who received ECMO support from December 2013 to April 2023. Univariate and multivariable logistic regression analyses were used to identify risk factors. The cutoff value was determined by receiver operating characteristic (ROC) curve analysis. Results: A total of 199 patients were selected for this study, and the mortality rate was 76.38%. More than half of the patients underwent surgery during hospitalization. Multivariable logistic regression analysis revealed that continuous renal replacement therapy (CRRT) implantation (OR = 2.994; 95% CI, 1.405-6.167; p = 0.004) and age (OR = 1.021; 95% CI, 1.002-1.040; p = 0.032) were the independent risk factors for mortality. In the ROC curve analysis, age had the best predictive effect (AUC 0.646, 95% CI 0.559-0.732, p = 0.003) for death when the cutoff value was 48.5 years. Furthermore, in patients receiving combined CRRT and ECMO, lack of congenital heart disease and previous surgical history were the independent risk factors for mortality. Conclusions: CRRT implantation and age were independent risk factors for patients with ECMO implantation in a predominantly surgical cohort. In patients receiving a combination of CRRT and ECMO, lack of congenital heart disease and previous surgical history were independent risk factors for mortality.
[Risk factors associated with in-hospital mortality in patients requiring extracorporeal membrane oxygenation in the perioperative period of heart transplantation]

X Hao,C L Li,H X Xie,F Yang,C J Jiang,Z T Du,X M Wang,H Wang,F L Hei,X T Hou

DOI: https://doi.org/10.3760/cma.j.cn112137-20230330-00516

2023-07-11

Abstract:Objective: To explore risk factors associated with in-hospital mortality in patients requiring extracorporeal membrane oxygenation (ECMO) in the perioperative period of heart transplantation. Methods: The data of ECMO cases in the perioperative period of heart transplantation from the Chinese Society of Extracorporeal Life Support (CSECLS) between January 2017 and December 2021 were retrospectively analyzed. These patients were divided into the survival group and non-survival group according to their outcomes at discharge. The demographics, indications and complications of ECMO between the two groups were compared, and the related risk factors of poor prognosis were analyzed. Results: A total of 77 patients were included in the study, including 67 males and 10 females, with a median age [M(Q1, Q3)] of 48 (36, 59) years. Sixty-three patients (81.8%) were successfully withdrawn from the ECMO and 46 patients (59.7%) survived to discharge. The median ECMO time was 139 (92, 253) hours. Compared with the survival group, the non-survival group (n=31) had more patients with chronic kidney disease before surgery [22.6% (7/31) vs 4.3% (2/46), P=0.034], and a higher proportion of continuous renal replacement therapy (CRRT) during ECMO [74.2% (23/31) vs 50.0% (23/46), P=0.034]. Moreover, the non-survival group had longer duration of extracorporeal circulation [262 (195, 312) vs 201 (155, 261) min, P=0.056] and higher lactate value in the first 24 hours of ECMO support [2.7 (2.1, 4.7) vs 2.3 (1.4, 3.8) mmol/L, P=0.060], but the differences were not statistically significant. Multivariate logistic regression analysis showed that perioperative application of CRRT was an independent risk factor for poor prognosis in ECMO patients during heart transplantation (OR=19.345, 95%CI: 1.209-309.440, P=0.036). Conclusion: CRRT treatment during ECMO is a risk factor for in-hospital mortality in patients undergoing heart transplantation.
Predictors associated with mortality of veno-venous extracorporeal membrane oxygenation therapy

Elena Neumann,Sebastian D Sahli,Alexander Kaserer,Julia Braun,Muriel A Spahn,Raed Aser,Donat R Spahn,Markus J Wilhelm

DOI: https://doi.org/10.21037/jtd-22-1273

2023-05-30

Abstract:Background: The use of veno-venous extracorporeal membrane oxygenation (V-V ECMO) has rapidly increased in recent years. Today, applications of V-V ECMO include a variety of clinical conditions such as acute respiratory distress syndrome (ARDS), bridge to lung transplantation and primary graft dysfunction after lung transplantation. The purpose of the present study was to investigate in-hospital mortality of adult patients undergoing V-V ECMO therapy and to determine independent predictors associated with mortality. Methods: This retrospective study was conducted at the University Hospital Zurich, a designated ECMO center in Switzerland. Data was analyzed of all adult V-V ECMO cases from 2007 to 2019. Results: In total, 221 patients required V-V ECMO support (median age 50 years, 38.9% female). In-hospital mortality was 37.6% and did not statistically vary significantly between indications (P=0.61): 25.0% (1/4) for primary graft dysfunction after lung transplantation, 29.4% (5/17) for bridge to lung transplantation, 36.2% (50/138) for ARDS and 43.5% (27/62) for other pulmonary disease indications. Cubic spline interpolation showed no effect of time on mortality over the study period of 13 years. Multiple logistic regression modelling identified significant predictor variables associated with mortality: age [odds ratio (OR), 1.05; 95% confidence interval (CI): 1.02-1.07; P=0.001], newly detected liver failure (OR, 4.83; 95% CI: 1.27-20.3; P=0.02), red blood cell transfusion (OR, 1.91; 95% CI: 1.39-2.74; P<0.001) and platelet concentrate transfusion (OR, 1.93; 95% CI: 1.28-3.15; P=0.004). Conclusions: In-hospital mortality of patients receiving V-V ECMO therapy remains relatively high. Patients' outcomes have not improved significantly in the observed period. We identified age, newly detected liver failure, red blood cell transfusion and platelet concentrate transfusion as independent predictors associated with in-hospital mortality. Incorporating such mortality predictors into decision making with regards to V-V ECMO use may increase its effectiveness and safety and may translate into better outcomes.
Fresh Frozen Plasma in Cases of Acute Upper Gastrointestinal Bleeding Does Not Improve Outcomes

Shuang Liu,Xiaoming Zhang,Joseph Harold Walline,Xuezhong Yu,Huadong Zhu

DOI: https://doi.org/10.3389/fmed.2022.934024

2022-07-14

Abstract:Background: Blood products are commonly transfused in patients with acute upper gastrointestinal bleeding (UGIB). There exists considerable practice variation and less evidence to guide fresh frozen plasma transfusion in patients with UGIB. The aim of this study was to explore any association between fresh frozen plasma transfusion following acute UGIB and clinical outcomes. Methods: This was a prospective, observational, multicenter study conducted at 20 tertiary hospitals in China. Patients with acute UGIB with an international normalized ratio ≤ 2.0 at emergency department admission were included. Multivariate logistic regression models were used to examine and quantify any clinical associations. Results: A total of 976 patients (61.57 ± 15.79 years old, 73.05% male) were included, of whom 17.42% received fresh frozen plasma transfusion. The overall 90-day mortality and rebleeding rates were 10.20 and 12.19%, respectively. After adjusting for confounding factors, transfusion of fresh frozen plasma during hospitalization was associated with higher 90-day mortality [odd ratio (OR), 2.36; 95% confidence interval (CI), 1.36-4.09; p = 0.002] but not rebleeding (OR, 1.5; 95% CI; 0.94-2.54; p = 0.085). In a subgroup analysis, patients with an international normalized ratio <1.5 who were treated with fresh frozen plasma were associated with both significantly higher 90-day mortality (OR, 2.78; 95% CI, 1.49-5.21; p = 0.001) and rebleeding (OR, 2.02; 95% CI, 1.16-3.52; p = 0.013), whereas in patients with an international normalized ratio between 1.5 and 2, we did not find any significant correlation. Conclusion: This study found an association between fresh frozen plasma transfusion following acute UGIB and elevated 90-day mortality. Both 90-day mortality and rebleeding risk were significantly higher in patients with an international normalized ratio < 1.5. Fresh frozen plasma transfusion in acute UGIB does not improve the poor outcomes (Chinese Clinical Trial registry, Number ChiCTR1900028676).
Platelet versus fresh frozen plasma transfusion for coagulopathy in cardiac surgery patients

Jake V. Hinton,Calvin M. Fletcher,Luke A. Perry,Noah Greifer,Jessica N. Hinton,Jenni Williams-Spence,Reny Segal,Julian A. Smith,Christopher M. Reid,Laurence Weinberg,Rinaldo Bellomo

DOI: https://doi.org/10.1371/journal.pone.0296726

IF: 3.7

2024-01-18

PLoS ONE

Abstract:Platelets (PLTS) and fresh frozen plasma (FFP) are often transfused in cardiac surgery patients for perioperative bleeding. Their relative effectiveness is unknown. We conducted an entropy-weighted retrospective cohort study using the Australian and New Zealand Society of Cardiac and Thoracic Surgeons National Cardiac Surgery Database. All adults undergoing cardiac surgery between 2005–2021 across 58 sites were included. The primary outcome was operative mortality. Of 174,796 eligible patients, 15,360 (8.79%) received PLTS in the absence of FFP and 6,189 (3.54%) patients received FFP in the absence of PLTS. The median cumulative dose was 1 unit of pooled platelets (IQR 1 to 3) and 2 units of FFP (IQR 0 to 4) respectively. After entropy weighting to achieve balanced cohorts, FFP was associated with increased perioperative (Risk Ratio [RR], 1.63; 95% Confidence Interval [CI], 1.40 to 1.91; P<0.001) and 1-year (RR, 1.50; 95% CI, 1.32 to 1.71; P<0.001) mortality. FFP was associated with increased rates of 4-hour chest drain tube output (Adjusted mean difference in ml, 28.37; 95% CI, 19.35 to 37.38; P<0.001), AKI (RR, 1.13; 95% CI, 1.01 to 1.27; P = 0.033) and readmission to ICU (RR, 1.24; 95% CI, 1.09 to 1.42; P = 0.001). In perioperative bleeding in cardiac surgery patient, platelets are associated with a relative mortality benefit over FFP. This information can be used by clinicians in their choice of procoagulant therapy in this setting.

multidisciplinary sciences
Predictors of red blood cell transfusion and its association with prognosis in patients undergoing extracorporeal membrane oxygenation

Hugo Lo Pinto,Jérôme Allyn,Romain Persichini,Bruno Bouchet,Gilbert Brochier,Olivier Martinet,Caroline Brulliard,Dorothée Valance,Benjamin Delmas,Eric Braunberger,Laurence Dangers,Nicolas Allou

DOI: https://doi.org/10.1177/0391398818785132

2018-07-12

The International Journal of Artificial Organs

Abstract:Purpose: Few data are available on the potential benefits and risks of red blood cell transfusion in patients undergoing extracorporeal membrane oxygenation. The aim of this study was to identify the determinants and prognosis of red blood cell transfusion in patients undergoing extracorporeal membrane oxygenation, with a special focus on biological parameters during extracorporeal membrane oxygenation treatment. Methods: We conducted a single-center retrospective cohort study including all consecutive patients who underwent extracorporeal membrane oxygenation between January 2010 and December 2015. Results: The 201 evaluated patients received a median of 0.9 [0.5–1.7] units of red blood cell per day. Significant and clinically relevant variables that best correlated with units of red blood cell transfused per day of extracorporeal membrane oxygenation were lower median daily prothrombin time in percentage (Quick) ( t = –0.016, p < 0.0001), higher median daily free bilirubin level ( t = 0.016, p < 0.0001), and lower pH ( t = –2.434, p < 0.0001). In multivariate analysis, red blood cell transfusion was associated with a significantly higher rate of in-intensive care unit mortality (per red blood cell unit increment; adjusted odds ratio: 1.07, 95% confidence interval: 1.02–1.12, p = 0.005). It was also associated with higher rates of acute renal failure ( p = 0.025), thromboembolic complications ( p = 0.0045), and sepsis ( p = 0.015). Conclusion: This study suggests that red blood cell transfusion may be associated with a higher mortality rate and with severe complications. However, we cannot conclude a direct causal relationship, as red blood cell transfusion may be only a marker of poor outcome. We recommend that physicians correct acidosis and hemolysis in patients undergoing extracorporeal membrane oxygenation whenever possible.
Impact of extracorporeal membrane oxygenation-related complications on in-hospital mortality

Eunae Byun,Pil Je Kang,Sung Ho Jung,Seo Young Park,Sang Ah Lee,Tae-Won Kwon,Yong-Pil Cho

DOI: https://doi.org/10.1371/journal.pone.0300713

IF: 3.7

2024-03-26

PLoS ONE

Abstract:Although extracorporeal membrane oxygenation (ECMO) is a well-established treatment for supporting severe cardiopulmonary failure, the morbidity and mortality of patients requiring ECMO support remain high. Evaluating and correcting potential risk factors associated with any ECMO-related complications may improve care and decrease mortality. This study aimed to assess the predictors of ECMO-related vascular and cerebrovascular complications among adult patients and to test the hypothesis that ECMO-related complications are associated with higher in-hospital mortality rates. This single-center, retrospective study included 856 ECMO runs administered via cannulation of the femoral vessels of 769 patients: venoarterial (VA) ECMO ( n = 709, 82.8%) and venovenous (VV) ECMO ( n = 147, 17.2%). The study outcomes included the occurrence of ECMO-related vascular and cerebrovascular complications and in-hospital death. The association of ECMO-related complications with the risk of in-hospital death was analyzed. The incidences of ECMO-related vascular and cerebrovascular complications were 20.2% and 13.6%, respectively. The overall in-hospital mortality rate was 48.7%: 52.8% among VA ECMO runs and 29.3% among VV ECMO runs. Multivariable analysis indicated that age ( P < 0.01), cardiopulmonary cerebral resuscitation ( P < 0.01), continuous renal replacement therapy ( P < 0.01), and initial platelet count [<50×10 3 /μL ( P = 0.02) and 50–100(×10 3 )/μL ( P < 0.01)] were associated with an increased risk of in-hospital death. ECMO-related vascular and cerebrovascular complications were not independently associated with higher in-hospital mortality rates for VA or VV ECMO runs. ECMO-related vascular and cerebrovascular complications were not associated with an increased risk of in-hospital death among adult patients.

multidisciplinary sciences
Aggressive fresh frozen plasma (FFP) with massive blood transfusion in the absence of acute traumatic coagulopathy

Biswadev Mitra,Peter A Cameron,Russell L Gruen

DOI: https://doi.org/10.1016/j.injury.2011.10.011

IF: 2.687

Injury

Abstract:Introduction: A high ratio of fresh frozen plasma (FFP) to packed red blood cells (PRBC) is currently recognised as the standard of care in some centres during massive transfusion post trauma. The aim of this study was to test whether the presumption of benefit held true for severely injured patients who received a massive transfusion, but did not present with acute traumatic coagulopathy. Patients and methods: Data collected in The Alfred Trauma Registry over a 6 year period were reviewed. Included patients were sub-grouped by a high FFP:PRBC ratio (≥1:2) in the first 4 h and compared to patients receiving a lower ratio. Outcomes studied were associations with mortality, hours in the intensive care unit and hours of mechanical ventilation. Results: Of 4164 eligible patients, 374 received a massive transfusion and 179 (49.7%) patients who did not have coagulopathy were included for analysis. There were 66 patients who received a high ratio of FFP:PRBC, and were similar in demographics and presentation to 113 patients who received a lower ratio. There was no significant difference in mortality between the two groups (p=0.80), and the FFP:PRBC ratio was not significantly associated with mortality, ICU length of stay or mechanically ventilated hours. Conclusions: A small proportion of major trauma patients received a massive blood transfusion in the absence of acute traumatic coagulopathy. Aggressive FFP transfusion in this group of patients was not associated with significantly improved outcomes. FFP transfusion carries inherent risks with substantial costs and the population most likely to benefit from a high FFP:PRBC ratio needs to be clearly defined.
Outcomes from Adult Veno-Arterial Extracorporeal Membrane Oxygenation in a Cardiovascular Disease Center from 2009 to 2019

Sizhe Gao,Gang Liu,Shujie Yan,Song Lou,Guodong Gao,Qiang Hu,Qiaoni Zhang,Jiachen Qi,Weidong Yan,Qian Wang,Jian Wang,Bingyang Ji

DOI: https://doi.org/10.1177/0267659121993365

2021-01-01

Perfusion

Abstract:Introduction: Extracorporeal membrane oxygenation (ECMO) is an imperative short-term cardiopulmonary support device now. We aimed to provide a single-center experience of veno-arterial (V-A) ECMO management and identify the risk factors of in-hospital mortality. Methods: We conducted a retrospective review of adult patients who received V-A ECMO between 2009 and 2019 in a cardiovascular disease center. The risk factor analysis of in-hospital mortality was conducted. Results: The study reviewed 236 patients, with an overall survival rate of 68.2%. The survivors’ blood lactate concentration is significantly lower than non-survivors [7.4 (7.8) vs 11.1 (9.7), p = 0.002]. Patients who received heart transplantation were with higher in-hospital survival rate. Survivors developed less hepatic dysfunction, acute kidney injury and myocardial damage [23 (14.3%) vs 19 (25.3%), p = 0.039; 81 (50.3%) vs 51 (68%), p = 0.011; 24 (14.9%) vs 22 (29.3%), p = 0.009, respectively], with higher rate of continuous renal replacement therapy (CRRT) [56 (34.8%) vs 53 (70.7%), p < 0.001]. Fewer survivors’ 24 hours and total chest drainage was over 1000 mL, and the rate of re-exploration as well as red blood cell and platelet transfusion were lower in survivors. In multivariate analysis, female, pre-ECMO blood lactate concentration, hyperlipidemia, CRRT, and 24 hours chest drainage ⩾ 1000 mL were risk factors of early mortality. Conclusions: By providing a general description of V-A ECMO practice at a single-center in China. Post-heart transplant graft failure was associated with numerically, the greatest survival in our practice. Furthermore, female sex, pre-ECMO blood lactate concentration, hyperlipidemia, CRRT, and high blood loss in chest drains are predictors of mortality in patients who undergo V-A ECMO.
In COVID-19 Patients Supported with Extracorporeal Membrane Oxygenation, Intensive Care Unit Mortality Is Associated with the Blood Transfusion Rate

Maged Makhoul,Eldad J. Dann,Tatiana Mashiach,Oleg Pikovsky,Roberto Lorusso,Jamela Eisa,Halil I. Bulut,Ori Galante,Eduard Ilgiyaev,Gil Bolotin,Naomi Rahimi-Levene

DOI: https://doi.org/10.3390/jcm13237381

IF: 3.9

2024-12-05

Journal of Clinical Medicine

Abstract:Background: The COVID-19 pandemic markedly increased the number of patients with infection-related acute respiratory distress syndrome who required extracorporeal membrane oxygenation (ECMO) and multiple blood transfusions. This study aimed to assess a potential correlation between the daily rate of transfused blood products and the intensive care unit (ICU) outcome of ECMO-supported COVID-19 patients. Methods: Data were retrieved from the electronic databases of three Israeli tertiary care centers. All COVID-19 patients treated with ECMO for >3 days in these centers between July 2020 and November 2021 were included in the analysis. Results: The study incorporated 106 patients [median age 49 (17–73) years]. The median numbers of ECMO days and daily transfused packed red blood cell (PRBC) units were 20.5 (4–240) and 0.61 (0–2.82), respectively. In multivariate analysis, age ≥50 years was an independent factor for ICU mortality [odds ratio (OR) 4.47). In ECMO-supported patients for <38 days, transfusion of ≥0.85 units/day was associated with higher ICU mortality compared to that observed in patients transfused with <0.85 PRBC units/day (OR = 5.43; p < 0.004). Transfusion of ≥0.5 units/day combined with ECMO support of ≥38 days (OR = 17.9; p < 0.001) conferred the highest mortality risk. Conclusions: Three-quarters of patients <50 years old and half of patients ≥50 years were successfully discharged from ICU. Higher daily transfusion rates were associated with significantly increased ICU mortality, irrespective of ECMO duration. Reduced blood transfusion may improve the survival of these patients. This approach could also contribute to the measures taken to address the challenges of blood shortages occurring during pandemics and other global or national emergencies.

medicine, general & internal
Transfusion practice in patients receiving VV ECMO (PROTECMO): a prospective, multicentre, observational study

Gennaro Martucci,Matthieu Schmidt,Cara Agerstrand,Ali Tabatabai,Fabio Tuzzolino,Marco Giani,Raj Ramanan,Giacomo Grasselli,Peter Schellongowski,Jordi Riera,Ali Ait Hssain,Thibault Duburcq,Vojka Gorjup,Gennaro De Pascale,Sarah Buabbas,Whitney D Gannon,Kyeongman Jeon,Brian Trethowan,Vito Fanelli,Juan I Chico,Martin Balik,Lars M Broman,Antonio Pesenti,Alain Combes,Marco V Ranieri,Giuseppe Foti,Hergen Buscher,Kenichi Tanaka,Roberto Lorusso,Antonio Arcadipane,Daniel Brodie,International ECMO Network (ECMONet),Matteo Brioni,Luca Montini,Linda Bosa,Pierfrancesco Curcio,Eugenio Garofalo,Luis Martin-Villen,Raquel Garcìa-Álvarez,Marta Lopez Sanchez,Nuno Principe,Violeta Chica Saez,Juan Ignacio Chico,Vanesa Gomez,Joaquin Colomina-Climent,Andres Francisco Pacheco,Julien Goutay,Duburcq Thibault,Konstanty Szułdrzyński,Philipp Eller,Elisabeth Lobmeyr,Silvia Mariani,Pavel Suk,Michal Maly,Jakob Forestier,Lars Mikael Broman,Monica Rizzo,Tyler Holsworth,Alexis Serra,Dan Brodie,Yiorgos Alexandros Cavayas,Jay Menaker,Samuel Galvagno,Todd W Rice,Wilson E Grandin,Jose Nunez,Collette Cheplic,Ryan Rivosecchi,Young-Jae Cho,Ming Chit Kwan,Hend Sallam,Joy Ann Villanueva,Jeffrey Aliudin,Kota Hoshino,Yoshitaka Hara,Kollengode Ramanathan,Graeme Maclaren

DOI: https://doi.org/10.1016/S2213-2600(22)00353-8

Abstract:Background: In patients receiving venovenous (VV) extracorporeal membrane oxygenation (ECMO) packed red blood cell (PRBC) transfusion thresholds are usually higher than in other patients who are critically ill. Available guidelines suggest a restrictive approach, but do not provide specific recommendations on the topic. The main aim of this study was, in a short timeframe, to describe the actual values of haemoglobin and the rate and the thresholds for transfusion of PRBC during VV ECMO. Methods: PROTECMO was a multicentre, prospective, cohort study done in 41 ECMO centres in Europe, North America, Asia, and Australia. Consecutive adult patients with acute respiratory distress syndrome (ARDS) who were receiving VV ECMO were eligible for inclusion. Patients younger than 18 years, those who were not able to provide informed consent when required, and patients with an ECMO stay of less than 24 h were excluded. Our main aim was to monitor the daily haemoglobin concentration and the value at the point of PRBC transfusion, as well as the rate of transfusions. The practice in different centres was stratified by continent location and case volume per year. Adjusted estimates were calculated using marginal structural models with inverse probability weighting, accounting for baseline and time varying confounding. Findings: Between Dec 1, 2018, and Feb 22, 2021, 604 patients were enrolled (431 [71%] men, 173 [29%] women; mean age 50 years [SD 13·6]; and mean haemoglobin concentration at cannulation 10·9 g/dL [2·4]). Over 7944 ECMO days, mean haemoglobin concentration was 9·1 g/dL (1·2), with lower concentrations in North America and high-volume centres. PRBC were transfused on 2432 (31%) of days on ECMO, and 504 (83%) patients received at least one PRBC unit. Overall, mean pretransfusion haemoglobin concentration was 8·1 g/dL (1·1), but varied according to the clinical rationale for transfusion. In a time-dependent Cox model, haemoglobin concentration of less than 7 g/dL was consistently associated with higher risk of death in the intensive care unit compared with other higher haemoglobin concentrations (hazard ratio [HR] 2·99 [95% CI 1·95-4·60]); PRBC transfusion was associated with lower risk of death only when transfused when haemoglobin concentration was less than 7 g/dL (HR 0·15 [0·03-0·74]), although no significant effect in reducing mortality was reported for transfusions for other haemoglobin classes (7·0-7·9 g/dL, 8·0-9·9 g/dL, or higher than 10 g/dL). Interpretation: During VV ECMO, there was no universally accepted threshold for transfusion, but PRBC transfusion was invariably associated with lower mortality only when done with haemoglobin concentration of less than 7 g/dL. Funding: Extracorporeal Life Support Organization.
Extracorporeal Membrane Oxygenation for Pulmonary Embolism: A Systematic Review and Meta-Analysis

Jonathan Jia En Boey,Ujwal Dhundi,Ryan Ruiyang Ling,John Keong Chiew,Nicole Chui-Jiet Fong,Ying Chen,Lukas Hobohm,Priya Nair,Roberto Lorusso,Graeme MacLaren,Kollengode Ramanathan

DOI: https://doi.org/10.3390/jcm13010064

2023-12-22

Abstract:Background: The use of extracorporeal membrane oxygenation (ECMO) for high-risk pulmonary embolism (HRPE) with haemodynamic instability or profound cardiogenic shock has been reported. Guidelines currently support the use of ECMO only in patients with cardiac arrest or circulatory collapse and in conjunction with other curative therapies. We aimed to characterise the mortality of adults with HRPE treated with ECMO, identify factors associated with mortality, and compare different adjunct curative therapies. Methods: We conducted a systematic review and meta-analysis, searching four international databases from their inception until 25 June 2023 for studies reporting on more than five patients receiving ECMO for HRPE. Random-effects meta-analyses were conducted. The primary outcome was in-hospital mortality. A subgroup analysis investigating the outcomes with curative treatment for HRPE was also performed. The intra-study risk of bias and the certainty of evidence were also assessed. This study was registered with PROSPERO (CRD42022297518). Results: A total of 39 observational studies involving 6409 patients receiving ECMO for HRPE were included in the meta-analysis. The pooled mortality was 42.8% (95% confidence interval [CI]: 37.2% to 48.7%, moderate certainty). Patients treated with ECMO and catheter-directed therapy (28.6%) had significantly lower mortality (p < 0.0001) compared to those treated with ECMO and systemic thrombolysis (57.0%). Cardiac arrest prior to ECMO initiation (regression coefficient [B]: 1.77, 95%-CI: 0.29 to 3.25, p = 0.018) and pre-ECMO heart rate (B: -0.076, 95%-CI: -0.12 to 0.035, p = 0.0003) were significantly associated with mortality. The pooled risk ratio when comparing mortality between patients on ECMO and those not on ECMO was 1.51 (95%-CI: 1.07 to 2.14, p < 0.01) in favour of ECMO. The pooled mortality was 55.2% (95%-CI: 47.7% to 62.6%), using trim-and-fill analysis to account for the significant publication bias. Conclusions: More than 50% of patients receiving ECMO for HRPE survive. While outcomes may vary based on the curative therapy used, early ECMO should be considered as a stabilising measure when treating patients with HRPE. Patients treated concurrently with systemic thrombolysis have higher mortality than those receiving ECMO alone or with other curative therapies, particularly catheter-directed therapies. Further studies are required to explore ECMO vs. non-ECMO therapies in view of currently heterogenous datasets.
High Fresh Frozen Plasma to Red Blood Cell Ratio and Survival Outcomes in Blunt Trauma

Gaku Fujiwara,Yohei Okada,Wataru Ishii,Tadashi Echigo,Naoto Shiomi,Shigeru Ohtsuru

DOI: https://doi.org/10.1001/jamasurg.2024.3097

2024-08-21

Abstract:Importance: Current trauma-care protocols advocate early administration of fresh frozen plasma (FFP) in a ratio close to 1:1 with red blood cells (RBCs) to manage trauma-induced coagulopathy in patients with severe blunt trauma. However, the benefits of a higher FFP to RBC ratio have not yet been established. Objective: To investigate the effectiveness of a high FFP to RBC transfusion ratio in the treatment of severe blunt trauma and explore the nonlinear relationship between the ratio of blood products used and patient outcomes. Design, setting, and participants: This was a multicenter cohort study retrospectively analyzing data from the Japan Trauma Data Bank, including adult patients with severe blunt trauma without severe head injury (Injury Severity Score ≥16 and head Abbreviated Injury Scale <3) between 2019 and 2022. Exposures: Patients were categorized into 2 groups based on the ratio of FFP to RBC: the high-FFP group (ratio >1) and the low-FFP group (ratio ≤1). Main outcomes and measures: All-cause in-hospital mortality was the primary outcome. Additionally, the occurrence of transfusion-related adverse events was evaluated. Results: Among the 1954 patients (median [IQR] age, 61 [41-77] years; 1243 male [63.6%]) analyzed, 976 (49.9%) had a high FFP to RBC ratio. Results from logistic regression, weighted by inverse probability treatment weighting, demonstrated an association between the group with a high-FFP ratio and lower in-hospital mortality (odds ratio, 0.73; 95% CI, 0.56-0.93) compared with a low-FFP ratio. Nonlinear trends were noted, suggesting a potential ceiling effect on transfusion benefits. Conclusions and relevance: In this cohort study, a high FFP to RBC ratio was associated with favorable survival in patients with severe blunt trauma. These outcomes highlight the importance of revising the current transfusion protocols to incorporate a high FFP to RBC ratio, warranting further research on optimal patient treatment.
The early decline in platelet count is associated with increased adverse outcomes in non heparin-induced thrombocytopenia pediatric patients undergoing VA-ECMO

Yu Jin,He Wang,Chun Zhou,Peiyao Zhang,Zhangyu Lin,Wenting Wang,Peng Gao,Jia Liu,Jinping Liu

DOI: https://doi.org/10.1177/02676591241301614

2024-11-23

Perfusion

Abstract:Perfusion, Ahead of Print. IntroductionThe impact of non heparin-induced thrombocytopenia on the clinical outcomes for pediatric cardiac surgery patients who required veno-arterial extracorporeal membrane support (VA-ECMO) for failure to wean from cardiopulmonary bypass (CPB) is uncertain. This study aimed to investigate the relationship between thrombocytopenia and prognosis in these patients.MethodsThis retrospective study enrolled 96 pediatric patients (age < 18) who received VA-ECMO directly transitioned from CPB at Fuwai Hospital from January 2010 to June 2020. The association between relative decrease in platelet count (△PLT) post-ECMO 24 h and clinical outcomes was explored.ResultsThere were significant differences in Post-ECMO 24 h platelet counts, platelet count nadir, and duration of platelet decline between the survivors and non-survivors in CPB-ECMO groups. A positive correlation was found between △PLT post-ECMO 24 h and plasma-free hemoglobin (pFHb) (p = .014, r = 0.305), peak serum creatinine (p = .016, r = 0.299), peak AST (p = .014, r = 0.302), duration of platelet transfusion (p = .032, r = 0.270),The △PLT post-ECMO 24 h had predictive value on in-hospital mortality [(p < .001, AUROC = 0.781 (95% CI: 0.670–0.892)], massive bleeding (p = .001, AUROC 95% CI: 0.627–0.870), hemolysis (p = .046, AUROC 95% CI: 0.510–0.780), and nosocomial infection (p = .020, AUROC 95% CI: 0.536–0.801). Multivariate logistic regression showed that △PLT post-ECMO 24 h was associated with in-hospital mortality and hemolysis.ConclusionsThe relative early decrease in platelet count 24 h following transition to ECMO is associated with increased patient mortality, and is positively associated with adverse outcomes in pediatric cardiac surgery patients transferred from CPB to ECMO. Moreover, this decline rate can predict in-hospital survival, major bleeding, hemolysis, and hospital-acquired infections.

cardiac & cardiovascular systems,peripheral vascular disease

Biochemical studies of immune complexes. II. Purification of immune complexes from sera of patients with malignant melanoma.

Association of Pulmonary Artery Pressure Change with Post-Lung Transplantation Survival: Retrospective Analysis of China Registry

Critically Ill Patients with COVID-19 with ECMO and Artificial Liver Plasma Exchange

Association of perioperative transfusion of fresh frozen plasma and outcomes after cardiac surgery

Association Between Perioperative Plasma Transfusion and In-Hospital Mortality in Patients Undergoing Surgeries Without Massive Transfusion: A Nationwide Retrospective Cohort Study.

Hemostasis During Extracorporeal Membrane Oxygenation: More Questions

Haematological Trends and Transfusion during Adult Extracorporeal Membrane Oxygenation: A Single Centre Study

Risk factors for mortality in patients receiving extracorporeal membrane oxygenation

[Risk factors associated with in-hospital mortality in patients requiring extracorporeal membrane oxygenation in the perioperative period of heart transplantation]

Predictors associated with mortality of veno-venous extracorporeal membrane oxygenation therapy

Fresh Frozen Plasma in Cases of Acute Upper Gastrointestinal Bleeding Does Not Improve Outcomes

Platelet versus fresh frozen plasma transfusion for coagulopathy in cardiac surgery patients

Predictors of red blood cell transfusion and its association with prognosis in patients undergoing extracorporeal membrane oxygenation

Impact of extracorporeal membrane oxygenation-related complications on in-hospital mortality

Aggressive fresh frozen plasma (FFP) with massive blood transfusion in the absence of acute traumatic coagulopathy

Outcomes from Adult Veno-Arterial Extracorporeal Membrane Oxygenation in a Cardiovascular Disease Center from 2009 to 2019

In COVID-19 Patients Supported with Extracorporeal Membrane Oxygenation, Intensive Care Unit Mortality Is Associated with the Blood Transfusion Rate

Transfusion practice in patients receiving VV ECMO (PROTECMO): a prospective, multicentre, observational study

Extracorporeal Membrane Oxygenation for Pulmonary Embolism: A Systematic Review and Meta-Analysis

High Fresh Frozen Plasma to Red Blood Cell Ratio and Survival Outcomes in Blunt Trauma

The early decline in platelet count is associated with increased adverse outcomes in non heparin-induced thrombocytopenia pediatric patients undergoing VA-ECMO